ArticlePediatric cardiology2026
Recurrent Cardiac Arrest in a Pediatric Patient with Hypertrophic Cardiomyopathy and a Myocardial Bridge: Player or Spectator?
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial bridge (MB) is common in patients with hypertrophic cardiomyopathy (HCM), and can reduce coronary flow leading to myocardial ischemia, fibrosis, and malignant ventricular arrhythmias resulting in sudden cardiac arrest (SCA). However, MB has not been previously reported as an isolated, modifiable cause of recurrent SCA in pediatric HCM. To describe a case of HCM with recurrent SCA found to have left anterior descending (LAD) coronary artery MB, with resolution of recurrent SCA after MB unroofing. A 13-year-old male with HCM had an epicardial implantable cardioverter defibrillator (ICD) placed after his first SCA at age 8. Atenolol was started after his second SCA at age 12. After a third SCA he was transitioned to Nadolol and Mexiletine, and underwent transvenous ICD implantation due to delayed shock secondary to under-sensing on epicardial system. He had two additional episodes of SCA, for which he was started on Amiodarone and transferred to our institution for transplant evaluation in the setting of biventricular systolic dysfunction. During transplant evaluation, exercise stress test suggested the presence of ischemia. Cardiac catheterization revealed a 6 cm proximal LAD MB, with near occlusion during systole (Figure 1). He underwent LAD unroofing and remained asymptomatic at baseline activity level with no further episodes of SCA during the subsequent follow-up. MB can cause significant compression leading to compromised coronary flow and myocardial ischemia distinct from the intrinsic underlying cardiomyopathy in HCM. Modifiable causes should be considered in cases of recurrent SCA, as treatment may alter prognostic implications.
Indexed as
Identifiers
42640473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.